Which HER2+ Patients Should Receive T-DXd + Pertuzumab First-Line?

The 40.7-month PFS benchmark has shifted the conversation, but for some patients, frontline T-DXd is a clinical necessity.

From PIK3CA mutations to brain metastases and high visceral burden, certain high-risk profiles demand our most aggressive tools from day one. Drs. Iyengar, Jhaveri, and Makhlin discuss identifying the patients who can’t afford to wait for second-line therapy.